Horizon Finance (HRZN) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Net investment income for Q2 2024 was $12.9 million ($0.36 per share), down from $16.1 million ($0.54 per share) year-over-year, with total investment income of $25.7 million, mainly due to lower average earning debt investments.
Net asset value per share was $9.12 as of June 30, 2024, down from $9.71 at year-end 2023 and $11.07 a year ago.
Portfolio yield on debt investments was 15.9% for Q2 2024, with a diversified portfolio focused on technology, life sciences, healthcare, and sustainability sectors.
Maintains a robust investment pipeline and significant capacity to invest, supported by a deeply experienced management team.
Management remains optimistic about future prospects, citing strong portfolio yield, covered distributions for over six years, and strengthened liquidity.
Financial highlights
Total investment income for the six months ended June 30, 2024, was $51.8 million, down 7.7% from the prior year period.
Net investment income for the six months was $25.5 million, compared to $29.1 million for the same period in 2023.
Net realized gains for the six months were $2.5 million, versus net realized losses of $16.7 million in the prior year.
Net unrealized depreciation for the six months was $28.5 million, compared to $6.9 million in the prior year.
Dividend yield stands at 10.96%; cumulative distributions per share since IPO total $18.81.
Outlook and guidance
Management expects a return to portfolio growth in H2 2024, supported by a robust pipeline and committed backlog, with a focus on high-quality investments.
Monthly distributions of $0.11 per share declared for October, November, and December 2024.
The company believes current cash, operations, and credit facilities are sufficient to meet commitments for at least the next 12 months.
Latest events from Horizon Finance
- Supplemental distributions proposed to enhance shareholder value amid merger approval process.HRZN
Proxy Filing11 Mar 2026 - Portfolio growth resumed in Q4, with strong yields and a transformative merger ahead.HRZN
Q4 20254 Mar 2026 - Merger creates a $446M NAV BDC, delivering a 33% NAV premium and scale benefits.HRZN
Q2 20253 Feb 2026 - Net investment income fell, but portfolio growth and strong liquidity supported distributions.HRZN
Q3 202417 Jan 2026 - NII covered distributions in 2024, but NAV fell; strong yield and liquidity support 2025 growth.HRZN
Q4 202425 Dec 2025 - Vote sought on new investment management agreement; Board recommends approval for continuity.HRZN
Proxy Filing1 Dec 2025 - Shareholders will vote on director elections and auditor ratification, with robust governance in place.HRZN
Proxy Filing1 Dec 2025 - Shareholders to vote on a new investment management agreement after adviser's change in control.HRZN
Proxy Filing1 Dec 2025 - Vote on a new investment management agreement is urged following a change in adviser control.HRZN
Proxy Filing1 Dec 2025